HK Stock Market Move | CHINA RES MIXC (01209) rose over 4% in the afternoon; shopping mall retail sales saw significant growth against the trend. The company is fully distributing its interim core net profit.
China Resources Vientiane Life (01209) rose more than 4% in the afternoon. As of the time of publication, it was up 3.74%, priced at HKD 40.5, with a turnover of HKD 261 million.
CHINA RES MIXC (01209) rose over 4% in the afternoon. As of the time of writing, it was up 3.74%, trading at HKD 40.5, with a transaction volume of HKD 261 million.
In terms of news, CHINA RES MIXC achieved an operating revenue of RMB 9.22 billion in the first half of the year, a year-on-year increase of 8.1%; it realized a net profit attributable to the parent company of RMB 2.24 billion, a year-on-year increase of 10.3%. The retail sales of shopping centers operated during the first half reached RMB 148.5 billion, a year-on-year increase of 21.7%, accounting for 0.6% of the national total retail sales of consumer goods. Notably, the company declared an interim dividend and a special dividend, totaling HKD 0.977 per share, a year-on-year increase of 10.9%, distributing 100% of the interim core net profit, resulting in a current annualized dividend yield of 5.0%.
EB SECURITIES issued a research report stating that the company, as a leading player driven by commercial operations and property management, has strong barriers to entry, with retail sales growth of shopping centers outpacing the overall retail sector. With ample reserve projects, double-digit growth in core net profit, and a 100% distribution rate, it is currently a rare target in the property management sector that combines growth potential with certainty in shareholder returns.
Related Articles

How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.
How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.

RECOMMEND





